Cellect Announces Stem Cell Triumph

(RTTNews) - The shares of Cellect Biotechnology Ltd. (APOP) surged in the pre-market as it unveiled the stem cell technology breakthrough with hundred percent acceptance. Thursday, the company said its ApoGraft Stem Cell transplant has zero related adverse events.

The shares of Cellect closed at 7.11 on Wednesday broke open at 12.21 on Thursday and reached to a high of 13.39 on a volume of 900K.

The clinical stage company utilises apoptosis or programmed cell death in which mature cells will die and stem cells will survive and flourish. Cellect CEO Shai Yarkoni said, "These interim results further support that we are closer than ever to a world where stem cells are used to replace sick organs and damaged tissues."

Usually introduction of a mature cell into any foreign body can evoke immune reaction and rejection. Graft versus Host disease has been a challenge in stem cell transplant, especially when the donor is non-related to the patient. Hence, chemotherapy, antibiotics and recurrent hospitalization are required for transplantation and it involves several risks. Utilizing apoptosis inducing protein Cellect reported that it can safely and effectively create non-toxic mass of enriched stem cells.

The Israel based company said, the product is transplantable within less than 12 hours from donation through a simple process performed on the bedside after selective physiological elimination of immune reaction-causing cells. "The ApoGraft transplantation is intended to result in complete recovery of the patient's immune system with no related safety concerns in contrast to the significant morbidity or even death causing standard medical procedure."